glp-1 compounding crackdown news october 2025 US signals on compounded weight-loss drugs; Hims shares tumble Eli Lilly telehealth partners continue

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an n-terminally truncated peptide that is a major endogenous metabolite in vivo

Last reviewed: May 14, 2026 Last updated: May 14, 2026 Written by: Jay Hastings , CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

The perceived energy boost represents a secondary benefit of metabolic optimization rather than a primary drug effect

Semaglutide produces average weight loss of 10-15% of body weight

Coffee can worsen acid reflux and may irritate an already-sensitive stomach

Integrating GLP1s into a LiverFirst Treatment Strategy When considering GLP1 therapy for patients with liver complications linked to metabolic dysfunction, clinicians should assess both hepatic and metabolic status not just weight or A1C